TriLink BioTechnologies And Lonza Enter Into Non-exclusive License And Supply Agreement For CleanCap mRNA Capping Technology
Portfolio Pulse from Benzinga Newsdesk
TriLink BioTechnologies has entered into a non-exclusive license and supply agreement with Lonza for the use of its CleanCap mRNA capping technology. This partnership aims to enhance the development and manufacturing capabilities for mRNA-based therapies.
April 30, 2024 | 11:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Maravai LifeSciences, parent company of TriLink BioTechnologies, enters a significant partnership with Lonza for mRNA technology, potentially enhancing its market position.
The partnership between TriLink BioTechnologies and Lonza for the CleanCap mRNA capping technology is likely to be viewed positively by investors, as it could enhance Maravai LifeSciences' (MRVI) position in the rapidly growing mRNA therapy market. This agreement could lead to increased demand for Maravai's products and services, potentially boosting its revenue and profitability in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90